SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists
This study suggests that LDN may improve quality of life, reduce pain and fatigue, and enhance immune function, indicating potential benefits for supporting healthspan in aging individuals This study highlights how NAD+ levels decline in both mouse and human Alzheimers brain samples, and how boosting NAD+ may prevent and reverse neurodegeneration and cognitive decline
Good candidates for the combination Researchers already using tirzepatide who have plateaued represent the strongest candidates
At Evenly Clinic, glutathione therapy is prescribed and monitored by qualified dermatologists, ensuring visible results, reduced glutathione side effects, and long-term skin health
Wang XJ, Ebbert JO, Loftus CG, Rosedahl JK, Philpot LM
Catalase in Endothelial Cell Defence (PubMed, 1987) GSH Redox Cycle as the Primary H2O2 Defence in Endothelial Cells A landmark mechanistic study published on PubMed examined the relative importance of the GSH redox cycle and catalase in protecting cultured endothelial cells against extracellular hydrogen peroxide flux a critical mediator of polymorphonuclear leukocyte-induced oxidant injury
